paclitaxel liposome

ApprovedSmall molecule

paclitaxel liposome is one of 200 small molecule programs targeting Nasopharyngeal Carcinoma. It is currently in Approved.

Indications

Total Trials

Active Trials

199

Competitors

Pipeline

Status by Indication[3][1]

Indication

Nasopharyngeal CarcinomaActive, not recruiting

Lung CancerActive, not recruiting

Esophageal CancerActive, not recruiting

Breast CancerActive, not recruiting

Pancreatic CancerActive, not recruiting

Ovarian CancerRecruiting

Gastric CancerActive, not recruiting

Nasopharyngeal CarcinomaPhase 2

Active, not recruiting

Lung CancerApproved

Active, not recruiting

Esophageal CancerPhase 3

Active, not recruiting

Breast CancerApproved

Active, not recruiting

Pancreatic CancerApproved

Active, not recruiting

Ovarian CancerPhase 2

Recruiting

Gastric CancerPhase 2

Active, not recruiting

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

paclitaxel liposome

UUnknown Sponsor

Approved

1 2

Nolvadex

SSan Diego Pacific Oncology & Hematology Associates

Preclinical

78 3

DATROWAY

Daiichi Sankyo

Preclinical

4 4

Megace

Bristol-Myers Squibb

Preclinical

4 5

MS Contin

Merck & Co.

Preclinical

2 6

Zolymbus

AbbVie

Preclinical

1 7

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

3 8

Effexor

WWyeth-Lederle Vaccines

Preclinical

2 9

Chirocaine

PPurdue Pharma LP

Preclinical

1 10

Cortef

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 2Recruiting

Ovarian Cancer

NCT07125391

Clinical

Trials by Indication[1]

Nasopharyngeal Carcinoma2 trials

Induction Chemotherapy in Young Patients With Locoregionally Advanced Nasopharyngeal Carcinoma

Unknown status·SSun Yat-sen University·Phase 2·NCT03020329·37 enrolled

Reduced-dose Radiotherapy for Low-risk Stage III Patients With Nasopharyngeal Carcinoma

Unknown status·SSun Yat-sen University·Phase 2·NCT03668730·215 enrolled

Pancreatic Cancer1 trial

Efficacy and Safety of Paclitaxel Liposome and S-1 as First-line Therapy in \ Advanced Pancreatic Cancer Patients

Unknown status·FFudan University·Phase 4·NCT04217096·40 enrolled

Breast Cancer1 trial

Weekly and Every 3 Week Administration of Paclitaxel Liposome Injection in Metastatic Breast Cancer

Unknown status·UUnknown Sponsor·Phase 4·NCT02142790·120 enrolled

Advanced Solid Tumor1 trial

Dose Escalation and Pharmacokinetic Study of Paclitaxel Liposome Injection in Treating Patients With Advanced Solid Tumor After Failure From Conventional Treatments

Unknown status·UUnknown Sponsor·Phase 4·NCT01994031·36 enrolled

Gastric Cancer1 trial

Study on Neoadjuvant Chemotherapy for Advanced Gastric Cancer

Unknown status·PPeking University·Phase 2·NCT02163291·30 enrolled

4 more indications

Lung Cancer1 trial

Paclitaxel Liposome for Squamous Non-Small-cell Lung Cancer Study(LIPUSU)

Unknown status·UUnknown Sponsor·Phase 4·NCT02996214·536 enrolled

Esophageal Squamous Cell Cancer1 trial

SHR-1210 in Combination With Apatinib and Chemotherapy in Patients With Advanced Esophageal Squamous Cell Cancer

Unknown status·CChinese Academy of Medical Sciences·Phase 2·NCT03603756·45 enrolled

Esophageal Cancer1 trial

Paclitaxel Liposome and Cisplatin as First-line Chemotherapy in Patients With Metastatic Esophageal Cancer

Withdrawn·SShantou University Medical College·Phase 3·NCT01998347

Ovarian Cancer1 trial

Chemotherapy Combined With Propranolol Hydrochloride as Neoadjuvant Therapy for Advanced High-grade Serous Ovarian Cancer: A Prospective, Multicenter, Phase II Clinical Study

Recruiting·BBai-Rong Xia·Phase 2·NCT07125391·136 enrolled

Sources

References

[1]
ClinicalTrials.gov — 10 trial records for paclitaxel liposome. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — paclitaxel liposome compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for paclitaxel liposome. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Unknown Sponsor company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: UUnknown Sponsor

paclitaxel liposome

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Trials by Indication[1]

Nasopharyngeal Carcinoma2 trials

Pancreatic Cancer1 trial

Breast Cancer1 trial

Advanced Solid Tumor1 trial

Gastric Cancer1 trial

Lung Cancer1 trial

Esophageal Squamous Cell Cancer1 trial

Esophageal Cancer1 trial

Ovarian Cancer1 trial

References

Drug Info

Quick Facts

Related News